Products

  1. Home
  2. Products
  3. Bone & Mineral Metabolism
  4. IDKmonitor® Golimumab Drug Level ELISA (Health Canada)

IDKmonitor® Golimumab Drug Level ELISA (Health Canada)

Method: ELISA
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 10 µl
Species: Human
Incubation time: 2h 10m
Standard Range: 4.15-225 ng/ml
Size: 96 wells
Regulatory Status: Health Canada Licensed. Not for sale in the U.S.
Kit Manual: Download

The IDKmonitor® Golimumab Drug Level ELISA is intended to quantitatively determine free golimumab (therapeutic antibody against TNFα, e.g., SIMPONI®) in EDTA plasma and serum.

Health Canada Licensed. For Laboratory Professional Use Only.

Not for sale in the U.S. Please contact us to order or get a quote.

If you are in the U.S., you can purchase the RUO version of the Golimumab Drug Level ELISA.

Browse our other IDKmonitor® Golimumab ELISAs.

Test Principle of the IDKmonitor® Golimumab Drug Level ELISA

The IDKmonitor® Golimumab Drug Level ELISA is designed to determine the quantity of free golimumab (therapeutic antibody against TNFα) in EDTA plasma or serum samples.

In the first incubation step, free golimumab from the sample is bound to the specific monoclonal anti-golimumab antibody coated on the plate. To remove all unbound substances, a washing step is carried out. In a further incubation step, a peroxidase-labeled antibody is added. Tetramethylbenzidine (TMB) is used as a substrate for peroxidase. Finally, an acidic stop solution is added to terminate the reaction.

The color changes from blue to yellow. The intensity of the yellow color is directly proportional to the concentration of free golimumab in the sample. A dose-response curve of the absorbance unit (optical density, OD at 450 nm) vs. concentration is generated using the values obtained from the standard. The concentrations of free golimumab in the samples are determined directly from this curve.

Additional information

Weight 35.5 oz
Dimensions 6.5 × 10 × 4.5 in
Social media & sharing icons powered by UltimatelySocial

Become an IDK Insider!

Join our mailing list to receive the latest news and updates from Immundiagnostik, Inc.

 
 
 
 

You have Successfully Subscribed!